leadf
logo-loader
viewAdvaxis

Advaxis shares advance on progress in canine cancers

Advaxis shares advance after the immunotherapist prints upbeat data from a recent study involving canine osteosarcoma

boydogcat_56f068d14a618.jpg
Affects dogs and human children

Advaxis (NASDAQ: ADXS) shares advanced on Monday after the immunotherapist printed upbeat data from a recent study involving canine osteosarcoma.

The company announced that data from a dose-escalation study of ADXS-HER2 in canine osteosarcoma was published online on March 18 in Clinical Cancer Research, a journal of the American Association for Cancer Research.

HER2 is expressed in roughly 40% to 60% of pediatric and canine osteosarcomas and in pulmonary metastatic disease, providing strong rationale for HER2 targeted immunotherapy in these cancers.

This treatment with ADXS-HER2 reduced the incidence of metastatic disease and prolonged survival relative to a historical control group. The median survival time for the ADXS-HER2 treated dogs was 956 days, which was significantly longer than the 423 day median survival time of the historical control group.

Osteosarcoma is the most common primary bone tumor in dogs, with over 10,000 dogs diagnosed annually. Osteosarcoma is also the most common bone cancer in children and teenagers.

Advaxis shares closed up 12.3% at $9.25.

Quick facts: Advaxis

Price: 0.4336 USD

NASDAQ:ADXS
Market: NASDAQ
Market Cap: $28.72 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Davide Bosio previews hotly anticipated IPOs for Miramar Resources and Zebit

Davide Bosio from Shaw and Partners says it's been a terrific start to the listing process for Miramar Resources, a junior West Australia exploration company. ''We opened up the offer and closed literally on the same day raising $8mln''. Bosio adds that Zebit is still on track to list on the ASX...

21 hours, 51 minutes ago

2 min read